PHASE 2 STUDY OF TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR -ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE SUBJECTS WITH GENOTYPE 1. HEPATITIS C: WEEK 4 INTERIM RESULTS (vol 48, pg 4, 2008)

被引：0
|
作者：
Forns, X. [1 ]
Marcellin, P. [2 ]
Goeser, T. [3 ]
Ferenci, P. [4 ]
Nevens, F. [5 ]
Carosi, G. [6 ]
Drenth, J. P. [7 ]
De Backer, K. [8 ]
van Heeswijk, R. [8 ]
Vangeneugden, T. J. [8 ]
Picchio, G. [9 ]
Beumont-Mauviel, M. [8 ]
机构：
[1] Univ Barcelona, Liver Unit, Barcelona, Spain
[2] Hop Beaujon, Clichy, France
[3] Klinikum Univ Koln, Cologne, Germany
[4] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria
[5] Univ Hosp Gasthuisberg, Dept Hepatol, B-3000 Louvain, Belgium
[6] Univ Brescia, Clin Infect & Trop Dis, Brescia, Italy
[7] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[8] Tibotec BVBA, Mechelen, Belgium
[9] Tibotec Inc, Yardley, PA USA
来源：
HEPATOLOGY | 2008年 / 48卷 / 06期
关键词：
D O I：
10.1002/hep.22702
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：2093 / 2093
页数：1
相关论文
共 50 条
  • [1] PHASE 2 STUDY OF TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR-ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE SUBJECTS WITH GENOTYPE 1 HEPATITIS C: WEEK 4 INTERIM RESULTS
    Forns, Xavier
    Marcellin, Patrick
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P.
    De Backer, Koen
    van Heeswijk, Rudolf
    Vangeneugden, Tony J.
    Picchio, Gaston
    Beumont-Mauviel, Maria
    HEPATOLOGY, 2008, 48 (04) : 1136A - 1137A
  • [2] VIROLOGICAL ANALYSIS OF PATIENTS RECEIVING TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR -ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE PATIENTS WITH GENOTYPE 1 HEPATITIS C: STUDY C208
    Marcellin, Patrick
    Forns, Xavier
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P.
    De Backer, Koen
    van Heeswijk, Rudolf
    Luo, Donghan
    Picchio, Gaston
    Beumont-Mauviel, Maria
    HEPATOLOGY, 2009, 50 (04) : 395A - 395A
  • [3] On-Treatment Response-Guided Therapy With Telaprevir Q8h or Q12h Combined With Peginterferon Alfa-2a or Peginterferon Alfa-2B and Ribavirin in Treatment-NaiVE Genotype 1 Hepatitis C (Study C208)
    Marcellin, Patrick
    Forns, Xavier
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P. H.
    Serfaty, Lawrence
    De Backer, Koen
    van Heeswijk, Rolf
    Luo, Don
    De Meyer, Sandra
    Beumont-Mauviel, Maria
    GASTROENTEROLOGY, 2010, 138 (05) : S847 - S847
  • [4] ON-TREATMENT RESPONSE-GUIDED THERAPY WITH TELAPREVIR Q8H OR Q12H COMBINED WITH PEGINTERFERON ALFA-2A PEGINTERFERON ALFA-2B AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HEPATITIS C (STUDY C208)
    Forns, X.
    Marcellin, P.
    Ferenci, P.
    Goeser, T.
    Nevens, F.
    Carosi, G.
    Drenth, J. P.
    Serfaty, L.
    De Backer, K.
    van Heeswijk, R.
    Luo, D.
    Picchio, G.
    Beaumont, M.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S26 - S26
  • [5] TELAPREVIR (TVR) q8h OR q12h COMBINED WITH EITHER PEGINTERFERON (PEG-IFN, P) ALFA-2A OR ALFA-2B AND RIBAVIRIN (RBV, R) IN TREATMENT-NAIVE GENOTYPE 1 HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY C208
    Colombo, M.
    Rumi, M. G.
    Carosi, G.
    Puoti, M.
    Marcellin, P.
    Forns, X.
    Goeser, T.
    Ferenci, P.
    Nevens, F.
    Drenth, J. P.
    Serfaty, L.
    Beumont-Mauviel, M.
    Picchio, G.
    DIGESTIVE AND LIVER DISEASE, 2010, 42 : S6 - S7
  • [6] Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Jacobson, Ira M.
    Everson, Gregory T.
    Gordon, Stuart C.
    Kauffman, Robert
    McNair, Lindsay
    Muir, Andrew
    McHutchison, John G.
    HEPATOLOGY, 2007, 46 (04) : 315A - 316A
  • [7] Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Mchutchison, J. G.
    Everson, G. T.
    Gordon, S. C.
    Jacobson, I.
    Kauffinan, R.
    McNair, L.
    Muir, A.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S4 - S4
  • [8] Prove1: Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Everson, Gregory T.
    Jacobson, Ira M.
    Gordon, Stuart C.
    McHutchison, John G.
    Kaufman, Robert
    McNair, Lindsay
    Muir, Andrew
    GASTROENTEROLOGY, 2008, 134 (04) : A758 - A758
  • [9] ACTIVITY OF TELAPREVIR MONOTHERAPY OR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE 4 HEPATITIS-C PATIENTS: FINAL RESULTS OF STUDY C210
    Benhamou, Yves
    Moussalli, Joseph
    Ratziu, Vlad
    Lebray, Pascal
    de Backer, Katrien
    Ghys, Anne
    van Heeswijk, Rolf
    Luo, Donghan
    Picchio, Gaston
    Beumont, Maria
    HEPATOLOGY, 2010, 52 (04) : 719A - 720A
  • [10] A PHASE 2B STUDY OF TELAPREVIR WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 NULL AND PARTIAL RESPONDERS AND RELAPSERS FOLLOWING A PRIOR COURSE OF PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: PROVE3 INTERIM RESULTS
    McHutchison, John G.
    Shiffman, Mitchell L.
    Terrault, Norah
    Manns, Michael P.
    Di Bisceglie, Adrian M.
    Jacobson, Ira M.
    Afdhal, Nezom H.
    Heathcote, E. Jenny
    Zeuzem, Stefan
    Reesink, Hendrik W.
    George, Shelley
    Adda, Nathalie
    Muir, Andrew J.
    HEPATOLOGY, 2008, 48 (04) : 431A - 432A
12345